Autoantibodies in chronic inflammatory demyelinating polyradiculoneuropathy

Area of Science:

• Neurology
• Immunology
• Pathophysiology

Background:

• Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) presents heterogeneously with varied clinical and immunopathological mechanisms.
• A subset of CIDP patients exhibits antibodies targeting proteins at the node of Ranvier, which are pathogenic and linked to specific phenotypes and treatment responses.

Purpose of the Study:

• To review novel insights gained from the discovery of autoantibodies in understanding CIDP.
• To highlight the clinical significance and pathophysiological implications of these autoantibody discoveries in CIDP.

Main Methods:

• Review of recent reports and scientific literature on autoantibodies in CIDP.
• Analysis of associations between specific autoantibodies (anti-NF155, anti-CNTN1) and clinical presentations, pathological features, and treatment outcomes.

Main Results:

• Antineurofascin 155 (NF155) antibodies are associated with tremor, ataxia, poor IVIG response, and distinct pathology in CIDP.
• Nephrotic syndrome is linked to anticontactin 1 (CNTN1) and antinodal neurofascin antibodies.
• Complement-fixing IgG3 antibodies against paranodal proteins correlate with acute-onset CIDP.
• Detection of these autoantibodies aids in selecting CIDP patients for rituximab treatment.
• Anti-CNTN1 and anti-NF155 antibodies are identified as the first pathogenic autoantibodies in CIDP.

Conclusions:

• Autoantibodies against nodal and paranodal proteins are crucial for clinical practice in CIDP.
• These discoveries have revealed new pathophysiological mechanisms, clinical phenotypes, and prognostic factors within CIDP.
• The identification of these autoantibodies stimulates further research into other clinically relevant autoantibodies in CIDP.